B3GNT2P1

Across TCGA pan-cancer cohorts, B3GNT2P1 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated B3GNT2P1 data layer.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher B3GNT2P1 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated B3GNT2P1 expression acts as an unfavorable survival marker.

HNSC, LUAD, and CHOL are the cancer types where B3GNT2P1 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.001	0.643	<.001	36	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	36	view →
CHOL	OS	Tertile	II,III,IV	0.019	0.675	<.001	36	view →
KIRP	OS	Tertile	III,IV	0.268	0.808	.012	18	view →
BLCA	DFS	Tertile	III,IV	0.155	0.471	.032	9	view →
ESCA	OS	Tertile	All	0.406	0.888	.045	6	view →
LUSC	OS	Tertile	II,III,IV	0.376	0.637	.037	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

B3GNT2P1–HNSC (OS)

Open the HNSC breakdown →